Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18184250 | 0.91 | TSHR (0.45) | P2RY14NOTUMKMT2ATP53NPC1 | |
| SCHEMBL20533433 | 0.91 | P2RY14 (0.44) | P2RY14KMT2ATP53NPC1RAB9A | |
| SCHEMBL18172408 | 0.90 | P2RY14 (0.47) | P2RY14NOTUMF2CCR1KMT2A | |
| SCHEMBL18172462 | 0.85 | CCR1 (0.46) | P2RY14NOTUMF2CCR1KMT2A | |
| SCHEMBL18172406 | 0.85 | CCR1 (0.46) | P2RY14NOTUMF2CCR1KMT2A | |
| SCHEMBL18172354 | 0.84 | CCR1 (0.41) | P2RY14NOTUMF2CCR1KMT2A | |
| SCHEMBL18172363 | 0.83 | P2RY14 (0.41) | P2RY14NOTUMF2CCR1KMT2A | |
| SCHEMBL18172460 | 0.82 | P2RY14 (0.62) | P2RY14NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18172452 | 0.82 | NOTUM (0.40) | P2RY14NOTUMCCR1 | |
| SCHEMBL18172459 | 0.81 | P2RX3 (0.48) | P2RY14F2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207449-B | Tetrazole derivatives for the treatment of psychotic disorders | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | claimed |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-10-18 | — | — | US | claimed |
| CN-107207449-B | Tetrazole derivatives for the treatment of psychotic disorders | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10577332-B2 | Tetrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577332-B2 | Tetrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577332-B2 | Tetrazole derivatives | MC2R, MC3R, GABRR3 | P2RY14 3175/4885NOTUM 3821/4885F2 703/4885 |
| US-20180297961-A1 | TETRAZOLE DERIVATIVES | MC2R, MC3R, GABRR3 | P2RY14 3175/4885NOTUM 3821/4885F2 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.